Data / Drug companies / Actavis Pharma, Inc.
Actavis Pharma, Inc.: 33 products in the FDA NDC directory, labeler code 45963
Actavis Pharma, Inc. (labeler code 45963) lists 33 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 26 prescription drugs, 7 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 1, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 45963
- Products in commercial distribution
- 33
- Packages
- 50
- Finished drugs by generic name
- 12
- Prescription products
- 26
- Over the counter products
- 0
- Controlled substance products
- Schedule II 3
- Flagged as original packager
- 22 of 22 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 12
- Earliest marketing start
- May 1, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 24 | 72.7% |
| Drugs for further processing | 7 | 21.2% |
| New drug applications (NDA) | 2 | 6.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 78.8% |
| Drugs for further processing | 7 | 21.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Desipramine hydrochloride | 6 | 8 |
| Metoprolol succinate | 4 | 46 |
| Dextroamphetamine sulfate | 3 | 17 |
| Gabapentin | 3 | 91 |
| Docetaxel | 2 | 21 |
| Lactulose | 2 | 18 |
| Irinotecan hydrochloride | 1 | 12 |
| Bupropion hydrochloride | 1 | 67 |
| Topotecan hydrochloride | 1 | 4 |
| Fludarabine phosphate | 1 | 6 |
| Vinorelbine | 1 | 2 |
| Doxorubicin hydrochloride | 1 | 20 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated, extended release | 8 | 24.2% |
| Capsule | 6 | 18.2% |
| Tablet, film coated | 6 | 18.2% |
| Injection, solution | 3 | 9.1% |
| Capsule, extended release | 3 | 9.1% |
| Injection, solution, concentrate | 2 | 6.1% |
| Injection, powder, lyophilized, for solution | 2 | 6.1% |
| Solution | 2 | 6.1% |
| Tablet, extended release | 1 | 3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Metoprolol succinate | 45963-709 | Tablet, film coated, extended release | Drugs for further processing | May 1, 2025 |
| Metoprolol succinate | 45963-678 | Tablet, film coated, extended release | Drugs for further processing | May 1, 2025 |
| Metoprolol succinate | 45963-677 | Tablet, film coated, extended release | Drugs for further processing | May 1, 2025 |
| Metoprolol succinate | 45963-676 | Tablet, film coated, extended release | Drugs for further processing | May 1, 2025 |
| Metoprolol succinate | 45963-676 | Tablet, film coated, extended release | Generic drugs (ANDA) | February 3, 2020 |
| Metoprolol succinate | 45963-709 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 23, 2019 |
| Metoprolol succinate | 45963-678 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 23, 2019 |
| Metoprolol succinate | 45963-677 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 23, 2019 |
| Irinotecan hydrochloride | 45963-614 | Injection, solution | Generic drugs (ANDA) | March 12, 2015 |
| Vinorelbine | 45963-607 | Injection, solution | Generic drugs (ANDA) | March 1, 2015 |
| Bupropion Hydrochloride | 45963-142 | Tablet, extended release | Generic drugs (ANDA) | February 17, 2015 |
| Topotecan hydrochloride | 45963-615 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 5, 2015 |
| Fludarabine phosphate | 45963-609 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 5, 2015 |
| Doxorubicin hydrochloride | 45963-733 | Injection, solution | Generic drugs (ANDA) | November 1, 2014 |
| Docetaxel | 45963-765 | Injection, solution, concentrate | New drug applications (NDA) | September 1, 2014 |
| Docetaxel | 45963-734 | Injection, solution, concentrate | New drug applications (NDA) | September 1, 2014 |
| Dextroamphetamine sulfate | 45963-305 | Capsule, extended release | Generic drugs (ANDA) | June 19, 2014 |
| Dextroamphetamine sulfate | 45963-304 | Capsule, extended release | Generic drugs (ANDA) | June 19, 2014 |
| Dextroamphetamine sulfate | 45963-303 | Capsule, extended release | Generic drugs (ANDA) | June 19, 2014 |
| Gabapentin | 45963-557 | Capsule | Drugs for further processing | May 28, 2014 |
| Gabapentin | 45963-556 | Capsule | Drugs for further processing | May 28, 2014 |
| Gabapentin | 45963-555 | Capsule | Drugs for further processing | May 28, 2014 |
| Gabapentin | 45963-555 | Capsule | Generic drugs (ANDA) | April 23, 2014 |
| Gabapentin | 45963-557 | Capsule | Generic drugs (ANDA) | April 3, 2014 |
| Gabapentin | 45963-556 | Capsule | Generic drugs (ANDA) | April 3, 2014 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.